Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report.
CNS Oncol
; 12(3): CNS101, 2023 09 01.
Article
en En
| MEDLINE
| ID: mdl-37491842
Patients with leptomeningeal disease have few therapeutic options and poor treatment outcomes. Single-agent therapies have not yet been as successful in improving patient survival. In this paper, we discuss how combination therapy with proton craniospinal irradiation, bevacizumab, and pembrolizumab led to neurological improvement and disease regression. These results show that this novel combination may lead to a significant benefit not seen previously with these individual drugs given alone. We hope to lay a foundation for a novel therapeutic approach in a critically high need disease which has previously been thought to be resistant to radiotherapy or immunotherapy.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Protones
/
Irradiación Craneoespinal
Tipo de estudio:
Prognostic_studies
Límite:
Humans
/
Male
Idioma:
En
Revista:
CNS Oncol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos